首页> Bone> Combination therapy in the Col1a2<sup>G610C</sup> mouse model of Osteogenesis Imperfecta reveals an additive effect of enhancing LRP5 signaling and inhibiting TGFβ signaling on trabecular bone but not on cortical bone.

Combination therapy in the Col1a2<sup>G610C</sup> mouse model of Osteogenesis Imperfecta reveals an additive effect of enhancing LRP5 signaling and inhibiting TGFβ signaling on trabecular bone but not on cortical bone.

导出 OA

翻译打印收藏纠错

第一作者： Shannon,Kaupp

第一单位： Orthopedic Research Laboratories, Department of Orthopedic Surgery, Boston Children's Hospital, Boston, MA, USA.

作者： Shannon,Kaupp ^[1] ; Dan J,Horan ^[2] ; Kyung-Eun,Lim ^[2] ; Henry A,Feldman ^[3] ; Alexander G,Robling ^[2] ; Matthew L,Warman ^[4] ; Christina M,Jacobsen ^[5]

作者单位： Orthopedic Research Laboratories, Department of Orthopedic Surgery, Boston Children's Hospital, Boston, MA, USA. ^[1] Department of Anatomy and Cell Biology, Indiana University, Indianapolis, IN, USA. ^[2] Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA, USA. ^[3] Orthopedic Research Laboratories, Department of Orthopedic Surgery, Boston Children's Hospital, Boston, MA, USA; Department of Genetics, Harvard Medical School, Boston, MA, USA. ^[4] Divisions of Endocrinology and Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA. Electronic address: Christina.jacobsen@childrens.harvard.edu. ^[5]

关键词 LRP5 Osteogenesis Imperfecta Sclerostin TGFβ WNT